Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.85 |
| ▸ | RAF1 | P04049 | 16/20 | 0.85 |
| ▸ | RET | P07949 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | CDK2 | P24941 | 1/20 | 0.67 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.67 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.67 |
| ▸ | KIF5B | P33176 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051444 | 0.92 | BRAF (1.00) | BRAFRAF1RETFGFR1FLT1 | |
| SCHEMBL15077857 | 0.91 | BRAF (0.75) | BRAFRAF1RETKDR | |
| SCHEMBL15077860 | 0.89 | BRAF (0.80) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL15077859 | 0.88 | BRAF (0.89) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL15051942 | 0.87 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL15077873 | 0.86 | RAF1 (0.76) | BRAFRAF1RETFGFR1FLT1 | |
| SCHEMBL15077863 | 0.85 | RAF1 (0.74) | BRAFRAF1RETFGFR1FLT1 | |
| SCHEMBL15051582 | 0.83 | BRAF (1.00) | BRAFRAF1RETFGFR1FLT1 | |
| SCHEMBL15077861 | 0.83 | BRAF (0.86) | BRAFRAF1RETKIF5BKDR | |
| SCHEMBL15052582 | 0.83 | BRAF (1.00) | BRAFRAF1RETFGFR1FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785459-B2 | Quinazoline compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2014-07-22 | — | — | US | disclosed |
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165458-A1 | QUINAZOLINE COMPOUNDS AS KINASE INHIBITORS | CNKSR1, NRAS, HRAS | BRAF 8/4885RAF1 10/4885RET 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.